Combodart 0.5 mg / 0.4 mg hard capsules

  • Name:

    Combodart 0.5 mg / 0.4 mg hard capsules

  • Company:
    info
  • Active Ingredients:

    Dutasteride, Tamsulosin Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 13/12/17

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 13/12/2017
print

Print ViewKeyword Search SmPC

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Paediatric Suspension Active Ingredients Amoxicillin trihydrate
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin DUO Suspension 400/57mg Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
1 - 0 of 135 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 December 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 13 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 13 December 2017 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC:
Section 4.8: Clarification that 'ejaculation disorders' includes 'semen volume decreased'
Section 4.8: Correction of minor spelling errors
Section 5.1: Addition of paragraph on effects on sexual function

Updated on 13 December 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 May 2017 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2. QUALITATIVE AND QUANTITATIVE COMPOSITION - QRD updates

4.4 Special warnings and precautions for use -
Breast neoplasia - Repositioned paragraph and addition of epidemiological studies showed no increase in the risk of developing male breast cancer with the use of 5-alpha reductase inhibitorsARIs (see section 5.1). 
Prostate cancer and high grade tumours - information regarding the Reduce study and outcome.
Cardiovascular adverse events - incidence of cardiac failure in these trials was lower in all actively treated groups compared to the placebo group, and other data available for dutasteride or alpha1-adrenoceptor antagonists do not support a conclusion on increased cardiovascular risks (see section 5.1)
Layout of text has moved throughout.

5.1  Pharmacodynamic properties - removal of 'There have been no clinical studies conducted with Combodart'.
Information on two case control, epidemiological studies.
In a meta-analysis of 12-randomised, placebo- or comparator-controlled clinical studies (n=18,802) that evaluated the risks of developing cardiovascular adverse events from the use of dutasteride (by comparison with controls), no consistent statistically significant increase in the risk of heart failure (RR 1.05; 95% CI 0.71, 1.57), acute myocardial infarction (RR 1.00; 95% CI 0.77, 1.30) or stroke (RR 1.20; 95% CI 0.88, 1.64) were found.
The REDUCE trial did not identify any new cases of Gleason 8–10 prostate cancers.

5.2 Pharmacokinetic properties - QRD updates

Updated on 3 May 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Correction of spelling/typing errors
  • Improved presentation of PIL

Updated on 19 November 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to instructions about missed dose
  • Change to storage instructions
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to further information section
  • Change to date of revision
  • Change to MA holder contact details
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.
  • Correction of spelling/typing errors

Updated on 19 November 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2: added excipient with known effect - soya oil
Section 4.2 : Update to Adult, paediatric & oral use on who can take the medicine and how it is taken
Section 4.3: update to table reference
Section 4.4: update warning on cardiac failure, hypotension, renal failure, Intraoperative Floppy Iris Syndrome, Inhibitors of CYP3A4 and CYP2D6.
Section 4.5: update on drug interactions.
Section 4.6: update on breast feeding and fertility
Section 4.8: update on undesirable effects on Tamsulosin and who to report adverse events.
Section 5.1: addition of flow rate and update on cardiac failure.
Section 5.3: addition of a
lpha1- adrenoceptor antagonists details
Section 6.6: minor typographical update.
Section 9: update to lastest renewal authorisation

Updated on 15 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 15 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 - change to Ireland MAH address

Updated on 9 January 2014 PIL

Reasons for updating

  • Change of active ingredient
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects

Updated on 9 January 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC UPDATES

·        Minor editorial updates to sections 4.4, 4.8

·        Section 4.4

  • The follow text has been added to the “Hypotension Orthostatic” heading (previously “Orthostatic hypotension”)

In order to minimise the potential for developing postural hypotension the patient should be haemodynamically stable on alpha-blocker therapy prior to initiating use of PDE5 inhibitors.

Symptomatic: Caution is advised when alpha adrenergic blocking agents including tamsulosin are co-administered with PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil). Alpha adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension (see section 4.5).

o   The following text has been added

Inhibitors of CYP3A4 and CYP2D6

Concomitant administration of tamsulosin hydrochloride with strong inhibitors of CYP3A4 (e.g. ketoconazole), or to a lesser extent, with strong inhibitors of CYP2D6 (e.g. paroxetine) can increase tamsulosin exposure (see section 4.5). Tamsulosin hydrochloride is therefore not recommended in patients taking a strong CYP3A4 inhibitor and should be used with caution in patients taking a strong (e.g. paroxetine) CYP2D6 inhibitor.

 

Tamsulosin hydrochloride should be used with caution in patients taking a moderate CYP3A4 inhibitor (e.g. erythromycin) in combination with either strong (e.g. paroxetine) or moderate (e.g. terbinafine) CYP2D6 inhibitors, or in patients known to be poor metabolisers of CYP2D6.

 

·        Section 4.5

  • Addition of “PDE5 inhibitors” to the “Tamsulosin” section
  • The following text has been added to the “Tamsulosin” section

Concomitant administration of tamsulosin hydrochloride and ketoconazole (a strong CYP3A4 inhibitor) resulted in an increase of the Cmax and AUC of tamsulosin hydrochloride by a factor of 2.2 and 2.8 respectively. Concomitant administration of tamsulosin hydrochloride and paroxetine (a strong CYP2D6 inhibitor) resulted in an increase of the Cmax and AUC of tamsulosin hydrochloride by a factor of 1.3 and 1.6 respectively.  A similar increase in exposure is expected in CYP2D6 poor metabolisers as compared to extensive metabolisers when co-administered with a strong CYP3A4 inhibitor.  The effects of co-administration of both CYP3A4 and CYP2D6 inhibitors with tamsulosin hydrochloride have not been evaluated clinically, however there is a potential for significant increase in tamsulosin exposure. (see section 4.4).

 

·        Section 4.8

  • Reformat of this section
  • Addition of a clarification footnote 3 added to the table in relation to  sexual adverse events, “Impotence”, “Altered (decreased) libido” and “Ejaculation disorders”, stating the following:

These sexual adverse events are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse events may persist after treatment discontinuation. The role of dutasteride in this persistence is not known.

o   The “Post marketing data” had been divided into “Dutasteride” and “Tamsulosin”

  • Addition of Stevens-Johnson syndrome (very rare)

o   Addition of the following adverse events in relation to Dutasteride in the Post marketing section

Psychiatric disorders

Not known: Depression

 

and

 

Reproductive system and breast disorders

Not known: Testicular pain and testicular swelling

 

 

  • Addition of the following text in relation to Tamsulosin in the Post marketing Section:

In addition atrial fibrillation, arrhythmia, tachycardia and dyspnoea have been reported in association with tamsulosin use. The frequency of events and the role of tamsulosin in their causation cannot be reliably determined.

 

·        Section 5.2

o   In the “Metabolism” section dealing with Tamsulosin, it has additionally been advised to refer to section 4.4 and 4.5  with regards to inhibition of hepatic drug metabolising enzymes leading to increased exposure to tamsulosin.

 

·        Section 6.1

  • Clarification that the soya mentioned in Section 4.3 may be contained in the lecithin (excipient of the capsule shell).  This now reads:

Lecithin (may contain soya oil)

Updated on 23 December 2013 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC UPDATES

·        Minor editorial updates to sections 4.4, 4.8

·        Section 4.4

  • The follow text has been added to the “Hypotension Orthostatic” heading (previously “Orthostatic hypotension”)

In order to minimise the potential for developing postural hypotension the patient should be haemodynamically stable on alpha-blocker therapy prior to initiating use of PDE5 inhibitors.

Symptomatic: Caution is advised when alpha adrenergic blocking agents including tamsulosin are co-administered with PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil). Alpha adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension (see section 4.5).

·        Section 4.5

  • Addition of “PDE5 inhibitors” to the “Tamsulosin” section

·        Section 4.8

  • Reformat of this section
  • Addition of Stevens-Johnson syndrome (very rare)
  • Addition of Depression (frequency not known)
  • Addition of the following text in relation to Tamsulosin:

In addition atrial fibrillation, arrhythmia, tachycardia and dyspnoea have been reported in association with tamsulosin use. The frequency of events and the role of tamsulosin in their causation cannot be reliably determined.

·        Section 6.

  • Clarification that the soya mentioned in Section 4.3 may be contained in the lecithin (excipient of the capsule shell).  This now reads:

Lecithin (may contain soya oil)

 

 

 

Updated on 29 November 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions

Updated on 17 July 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 22 March 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to Section:

 

1.       NAME OF THE MEDICINAL PRODUCT

 

Duodart 0.5 mg / 0.4 mg hard capsules

 

 

4.4     Special warnings and precautions for use

 

 

Duodart Combination therapy should be prescribed after careful benefit risk assessment due to the potential increased risk of adverse events (including cardiac failure) and after consideration of alternative treatment options including monotherapies.

 

Cardiac failure

In twoa 4-year clinical studiesy, the incidence of cardiac failure (a composite term of reported events, primarily cardiac failure and congestive cardiac failure) was higher among subjects taking the combination of dutasteride and an alpha blocker, primarily tamsulosin, than it was among subjects not taking the combination.  In these two trials, the incidence of cardiac failure was low (≤1%) and variable between the studies  No causal relationship between dutasteride (alone or in combination with an alpha blocker) and cardiac failure has been established (see section 5.1).

 

Effects on prostate specific antigen (PSA) and prostate cancer detection

Digital rectal examination, as well as other evaluations for prostate cancer or other conditions which can cause the same symptoms as BPH, must be performed on patients with BPH prior to initiating therapy with Duodart and periodically thereafter.

 

Serum prostate-specific antigen (PSA) concentration is an important component in the detection of prostate cancer.  Generally, a total serum PSA concentration greater than 4 ng/mL (Hybritech) requires further evaluation and consideration of prostate biopsy.  Physicians should be aware that a baseline PSA less than 4 ng/mL in patients taking Duodart does not exclude a diagnosis of prostate cancer.  Duodart causes a decrease in mean serum PSA levels by approximately 50%, after 6 months of treatment., in patients with BPH, even in the presence of prostate cancer. 

 

Patients receiving Duodart should have a new PSA baseline established after 6 months of treatment with Duodart. It is recommended to monitor PSA values regularly thereafter.  Although there may be individual variation, the reduction in PSA by approximately 50% is predictable as it was observed over the entire range of baseline PSA values (1.5 to 10 ng/mL).  Therefore to interpret an isolated PSA value in a man treated with Duodart for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men.  This adjustment preserves the sensitivity and specificity of the PSA assay and maintains its ability to detect prostate cancer.  Any sustained confirmed increases from lowest in PSA levels while on Duodart may signal the presence of prostate cancer (particularly high grade cancer) or should be carefully evaluated, including consideration of noncompliance to therapy with Duodart and should be carefully evaluated, even if those values are still within the normal range for men not taking a 5a‑reductase inhibitor (see section 5.1).   In the interpretation of a PSA value for a patient taking dutasteride, previous PSA values should be sought for comparison.

 

Treatment with Duodart does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established (see section 5.1).

 

Total serum PSA levels return to baseline within 6 months of discontinuing treatment.  The ratio of free to total PSA remains constant even under the influence of Duodart.  If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing Duodart therapy, no adjustment to its value appears necessary.

 

 

Prostate cancer and high grade tumours

Results of one clinical study (the REDUCE study) in men at increase risk of prostate cancer revealed a higher incidence of Gleason 8 – 10 prostate cancers in dutasteride treated men compared to placebo.  The relationship between dutasteride and high grade prostate cancer is not clear.  Men taking Duodart should be regularly evaluated for prostate cancer risk including PSA testing (see section 5.1). 

 

Renal impairment

The treatment of severely renally impaired patients (creatinine clearance of less than 10 ml/min) should be approached with caution as these patients have not been studied.

 

Orthostatic hypotension

As with other alpha-blockers, a reduction in blood pressure can occur during treatment with tamsulosin, as a result of which, rarely, syncope can occur. Patients beginning treatment with Duodart should be cautioned to sit or lie down at the first signs of orthostatic hypotension (dizziness, weakness) until the symptoms have resolved.

 

Intraoperative Floppy Iris Syndrome

Intraoperative Floppy Iris Syndrome (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. IFIS may lead to increased procedural complications during the operation. The initiation of therapy with Duodart in patients for whom cataract surgery is scheduled is therefore not recommended.

 

During pre-operative assessment, cataract surgeons and ophthalmic teams should consider whether patients scheduled for cataract surgery are being or have been treated with Duodart in order to ensure that appropriate measures will be in place to manage the IFIS during surgery.

 

Discontinuing tamsulosin 1 – 2 weeks prior to cataract surgery is anecdotally considered helpful, but the benefit and duration of stopping therapy prior to cataract surgery has not yet been established.

 

Leaking capsules

Dutasteride is absorbed through the skin, therefore, women, children and adolescents must avoid contact with leaking capsules (see section 4.6).  If contact is made with leaking capsules, the contact area should be washed immediately with soap and water.

 

Hepatic impairment

Duodart has not been studied in patients with liver disease.  Caution should be used in the administration of Duodart to patients with mild to moderate hepatic impairment (see section 4.2, section 4.3 and section 5.2).

 

Excipients

This medicinal product contains the colouring agent Sunset Yellow (E110), which may cause allergic reactions.

 

Breast neoplasia

Breast cancer has been reported in men taking dutasteride in clinical trials (see section 5.1) and during the post-marketing period.  Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps or nipple discharge. Currently it is not clear if there is a causal relationship between the occurrence of male breast cancer and long term use of dutasteride.

 

 

4.6     Fertility, pregnancy and lactation

 

 

Pregnancy

 

As with other 5 alpha reductase inhibitors, dutasteride inhibits the conversion of testosterone to dihydrotestosterone and may, if administered to a woman carrying a male foetus, inhibit the development of the external genitalia of the foetus (see section 4.4).  Small amounts of dutasteride have been recovered from the semen in subjects receiving dutasteride. Based on studies in animals, it is unlikely that It is not known whether a male foetus will be adversely affected if his mother is exposed to the semen of a patient being treated with dutasteride (the risk of which is greatest during the first 16 weeks of pregnancy). However, a

 

As with all 5 alpha reductase inhibitors, when the patient's partner is or may potentially be pregnant it is recommended that the patient avoids exposure of his partner to semen by use of a condom.

 

Administration of tamsulosin hydrochloride to pregnant female rats and rabbits showed no evidence of foetal harm.

 

For information on preclinical data, see section 5.3.

 

 

 

4.8         Undesirable effects

 

 

Clinical Trial Data

 

 

 

<>Nervous system disorders

<>   Combinationa

 

   Dutasteride

   Tamsulosin

 

System Organ Class

Adverse Reaction

Incidence during treatment period

Year 1

Year 2

Year 3

Year 4

   Combinationa (n)

(n=1610)

(n=1428)

(n=1283)

(n=1200)

   Dutasteride

(n=1623)

(n=1464)

(n=1325)

(n=1200)

   Tamsulosin

(n=1611)

(n=1468)

(n=1281)

(n=1112)

Nervous system disorders

Dizziness

   Combinationa

   Dutasteride

   Tamsulosin

 

 

 

 

1.4%

0.7%

1.3%

0.1%

0.1%

0.4%

<0.1%

<0.1%

<0.1%

0.2%

<0.1%

0%

Cardiac disorders

Cardiac failure (composite termb)

 

 

 

 

 

   Combinationa

0.2%

0.4%

0.2%

0.2%

 

   Dutasteride

<0.1%

0.1%

<0.1%

0%

 

   Tamsulosin

0.1%

<0.1%

0.4%

0.2%

Reproductive system and breast disorders, Psychiatric disorders, Investigations

 

 

 

 

 

 

 

 

 

 

 

 

 

Nervous system disorders

Impotence

 

 

 

 

   Combinationa

6.3%

1.8%

0.9%

0.4%

   Dutasteride

5.1%

1.6%

0.6%

0.3%

   Tamsulosin

3.3%

1.0%

0.6%

1.1%

Altered (decreased) libido

 

 

 

 

   Combinationa

5.3%

0.8%

0.2%

0%

   Dutasteride

3.8%

1.0%

0.2%

0%

   Tamsulosin

2.5%

0.7%

0.2%

<0.1%

Ejaculation disorders

 

 

 

 

   Combinationa

9.0%

1.0%

0.5%

<0.1%

   Dutasteride

1.5%

0.5%

0.2%

0.3%

   Tamsulosin

2.7%

0.5%

0.2%

0.3%

Breast disordersbc

 

 

 

 

   Combinationa

2.1%

0.8%

0.9%

0.6%

   Dutasteride

1.7%

1.2%

0.5%

0.7%

   Tamsulosin

0.8%

0.4%

0.2%

0%

Dizziness

1.4%

0.7%

1.3%

0.1%

0.1%

0.4%

<0.1%

<0.1%

<0.1%

0.2%

<0.1%

0%

a           Combination = dutasteride 0.5 mg once daily plus tamsulosin 0.4 mg once daily.
b           Cardiac failure composite term comprised of Cardiac failure congestive, cardiac failure, left ventricular failure, cardiac failure acute, cardiogenic shock, left ventricular failure acute, right ventricular failure, right ventricular failure acute, ventricular failure, cardiopulmonary failure, congestive cardiomyopathy.

c         Includes breast tenderness and breast enlargement.

 

TAMSULOSIN MONOTHERAPY

 

Clinical Trial Data and Postmarketing Data

 

The adverse reactions and frequency categories listed in the table below are based on information available in the public domain. Common and uncommon reactions are consistent with those identified in a clinical trial setting and the frequency categories generally reflect incidence over placebo. Rare and very rare reactions are consistent with those identified from post marketing reports and the frequency categories reflect reporting rates.

 

 

Frequency Category

System Organ Class

Common          (≥1/100      <1/10)

Uncommon   (≥1/1000    <1/100)

Rare            (≥1/10,000 <1/1000)

Very rare (<1/10,000)
including isolated cases

Nervous system disorders

Dizziness

Headache

Syncope

 

Cardiac disorders

 

Palpitations

 

 

Vascular disorders

 

Postural hypotension

 

 

Respiratory, thoracic and mediastinal disorders

 

Rhinitis

 

 

Gastrointestinal disorders

 

Constipation Diarrhoea Nausea Vomiting

 

 

Skin and subcutaneous disorders

 

Rash, Pruritis, Urticaria

Angioedema

 

Reproductive system and breast disorders

 

Abnormal ejaculation

 

Priapism

General disorders and administration site disorders

 

Asthenia

 

 

Nervous system disorders

Dizziness

Headache

Syncope

 

Reproductive system and breast disorders

 

Abnormal ejaculation

 

Priapism

Respiratory, thoracic and mediastinal disorders

 

Rhinitis

 

 

Skin and subcutaneous disorders

 

Rash, Pruritis, Urticaria

Angioedema

 

Vascular disorders

 

Postural hypotension

 

 

 

During postmarketing surveillance, reports of Intraoperative Floppy Iris Syndrome (IFIS), a variant of small pupil syndrome, during cataract surgery have been associated with alpha-1 blocker therapy, including tamsulosin (see section 4.4).

 

 

OTHER DATA

 

The REDUCE study revealed a higher incidence of Gleason 8-10 prostate cancers in dutasteride treated men compared to placebo (see sections 4.4 and 5.1). Whether the effect of dutasteride to reduce prostate volume, or study related factors, impacted the results of this study has not been established.

 

 

The following has been reported in clinical trials and post-marketing use: male breast cancer (see section 4.4).

 

 

5.       PHARMACOLOGICAL PROPERTIES

 

5.1     Pharmacodynamic properties

 

 

Cardiac failure:

 

In this 4 year BPH study the incidence of the composite term cardiac failure in the combination group (14/1610, 0.9%) was higher than in either monotherapy group: dutasteride, (4/1623, 0.2%) and tamsulosin, (10/1611, 0.6%) (see section 4.4).

 

DUTASTERIDE

 

 

Cardiac failure:

 

In a 4 year BPH study of dutasteride in combination with tamsulosin in 4844 men (the CombAT study) the incidence of the composite term cardiac failure in the combination group (14/1610, 0.9%) was higher than in either monotherapy group:  dutasteride, (4/1623, 0.2%) and tamsulosin, (10/1611, 0.6%).

 

In a separate 4-year study in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL in the case of men 50 to 60 years of age, or 3 ng/mL and 10.0 ng/mL in the case of men older than 60 years of age) (the REDUCE study), there was a higher incidence of the composite term cardiac failure in subjects taking dutasteride 0.5 mg once daily (30/4105, 0.7%) compared to subjects taking placebo (16/4126, 0.4%).  A post-hoc analysis of this study showed a higher incidence of the composite term cardiac failure in subjects taking dutasteride and an alpha blocker concomitantly (12/1152, 1.0%), compared to subjects taking dutasteride and no alpha blocker (18/2953, 0.6%), placebo and an alpha blocker (1/1399, <0.1%), or placebo and no alpha blocker (15/2727, 0.6%).

 

 

Prostate cancer and high grade tumours

 

In a 4-year comparison of placebo and dutasteride in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10.0 ng/mL in the case of men 50 to 60 years of age, or 3 ng/mL and 10.0 ng/mL in the case of men older than 60 years of age) (the REDUCE study), 6,706 subjects had prostate needle biopsy (primarily protocol mandated) data available for analysis to determine Gleason Scores. There were 1517 subjects diagnosed with prostate cancer in the study.  The majority of biopsy-detectable prostate cancers in both treatment groups were diagnosed as low grade (Gleason 5-6, 70%).

 

There was a higher incidence of Gleason 8-10 prostate cancers in the dutasteride group (n=29, 0.9%) compared to the placebo group (n=19, 0.6%) (p=0.15).  In Years 1-2, the number of subjects with Gleason 8-10 cancers was similar in the dutasteride group (n=17, 0.5%) and the placebo group (n=18, 0.5%).  In Years 3-4, more Gleason 8-10 cancers were diagnosed in the dutasteride group (n=12, 0.5%) compared with the placebo group (n=1, <0.1%) (p=0.0035).  There are no data available on the effect of dutasteride beyond 4 years in men at risk of prostate cancer.  The percentage of subjects diagnosed with Gleason 8-10 cancers was consistent across study time periods (Years 1-2 and Years 3-4) in the dutasteride group (0.5% in each time period), while in the placebo group, the percentage of subjects diagnosed with Gleason 8-10 cancers was lower during Years 3-4 than in Years 1-2 (<0.1% versus 0.5%, respectively) (see section 4.4). There was no difference in the incidence of Gleason 7-10 cancers (p=0.81).

 

In a 4 year BPH study (CombAT) where there were no protocol-mandated biopsies and all diagnoses of prostate cancer were based on for-cause biopsies, the rates of Gleason 8-10 cancer were (n=8, 0.5%) for dutasteride, (n=11, 0.7%) for tamsulosin and (n=5, 0.3%) for combination therapy.

 

The relationship between dutasteride and high grade prostate cancer is not clear.  

 

 

 

5.3     Preclinical safety data

 

Non-clinical studies have not been conducted with Duodart. Dutasteride and tamsulosin hydrochloride individually have been extensively evaluated in animal toxicity tests and findings were consistent with the known pharmacological actions of 5 alpha‑reductase inhibitors and alpha-adrenergic blockers. The following statements reflect the information available on the individual components.

 

Dutasteride

 

Current studies of general toxicity, genotoxicity and carcinogenicity did not show any particular risk to humans.

 

Reproduction toxicity studies in male rats have shown a decreased weight of the prostate and seminal vesicles, decreased secretion from accessory genital glands and a reduction in fertility indices (caused by the pharmacological effect of dutasteride). The clinical relevance of these findings is unknown.

 

As with other 5 alpha reductase inhibitors, feminisation of male foetuses in rats and rabbits has been noted when dutasteride was administered during gestation. Dutasteride has been found in blood from female rats after mating with dutasteride treated males. When dutasteride was administered during gestation to primates, no feminisation of male foetuses was seen at blood exposures sufficiently in excess of those likely to occur via human semen. It is unlikely that a male foetus will be adversely affected following seminal transfer of dutasteride.

 

Tamsulosin

 

Studies of general toxicity and genotoxicity did not show any particular risk to humans other than those related to the pharmacological properties of tamsulosin.

 

In carcinogenicity studies in rats and mice, tamsulosin hydrochloride produced an increased incidence of proliferative changes of the mammary glands in females.  These findings, which are probably mediated by hyperprolactinaemia and only occurred at high dose levels, are regarded as not clinically relevant

 

High doses of tamsulosin hydrochloride resulted in a reversible reduction in fertility in male rats considered possibly due to changes of semen content or impairment of ejaculation.  Effects of tamsulosin on sperm counts or sperm function have not been evaluated.

 

Administration of tamsulosin hydrochloride to pregnant female rats and rabbits at higher than the therapeutic dose showed no evidence of foetal harm.

 

 

 

 

 

 

Updated on 21 March 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 2 December 2011 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Updates to SPC -

Section 4.3 - Addition of hypersentitity to excipient including soya & peanut

Section 4.5 - CORRECTION of 'Administration of 12 g cholestyramine one hour AFTER instead of BEFORE a 5 mg single dose of dutasteride

Section 4.8 - addition of Postmarketing Data, AE's

Updated on 30 November 2011 PIL

Reasons for updating

  • Change of inactive ingredient
  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 20 October 2011 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Typo

Updated on 19 October 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to Sections:

4.8
5.1

Updated on 25 May 2010 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 19 May 2010 PIL

Reasons for updating

  • New PIL for new product
  • New PIL for medicines.ie